RxDoctor Payments Data

Otakar Krcal, MD

Neurology · Kingsport, TNNPI 1396868022

Payments from drug & device makers

$26,394in general payments, 2019–2025

Across 1,460 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • AbbVie$2K
  • Novartis$2K
  • MDD US Operations, LLC$1K
  • Biogen$1K
  • AstraZeneca$1K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$1751%
  • Speaking & faculty fees$570%
  • Food & beverage$26,12099%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.134$2,744
AbbVie(2 entities)196$2,319
Novartis87$1,568
MDD US Operations, LLC46$1,099
Biogen62$1,072
AstraZeneca(2 entities)43$1,058
Neurelis, Inc.36$1,013
Lundbeck LLC58$966
Teva Pharmaceuticals USA, Inc.62$913
Lilly USA, LLC60$862
Eisai Inc.38$806
Neurocrine Biosciences, Inc.35$652
Sanofi29$573
Amgen29$573
Genentech USA, Inc.30$539
Kyowa Kirin, Inc.23$492
Supernus Pharmaceuticals, Inc.22$486
Jazz Pharmaceuticals Inc.19$456
TG Therapeutics, Inc.19$445
Pfizer30$433
EMD Serono, Inc.24$432
Sunovion Pharmaceuticals Inc.28$401
Bristol Myers Squibb22$392
Acadia Pharmaceuticals Inc23$374
Greenwich Biosciences, Inc.16$362
SK Life Science, Inc.15$325
Argenx US, Inc.16$318
Grifols USA, LLC17$305
Ipsen Biopharmaceuticals, Inc15$300
Johnson & Johnson19$287
Adamas Pharmaceuticals, Inc.13$278
Avanir Pharmaceuticals, Inc.15$263
CSL Behring8$214
Merz Pharmaceuticals, LLC9$193
Biohaven Pharmaceuticals, Inc.13$192
Amneal Pharmaceuticals LLC11$191
Otsuka America Pharmaceutical, Inc.11$189
Upsher-smith Laboratories LLC11$185
Catalyst Pharmaceuticals, Inc.9$183
Corium, LLC8$174
Scilex Pharmaceuticals Inc.9$164
Biohaven Pharmaceutical Holding Company Ltd.8$149
Mallinckrodt Hospital Products Inc.8$149
Harmony Biosciences LLC7$149
Vanda Pharmaceuticals Inc.5$110
Sumitomo Pharma America, Inc.9$104
Takeda Pharmaceuticals U.S.A., Inc.3$81
Amylyx Pharmaceuticals, Inc.3$75
E.r. Squibb & Sons, L.L.C.5$73
Impel Pharmaceuticals Inc.3$63
Tanabe Pharma America, Inc.4$54
Alnylam Pharmaceuticals Inc.3$50
Zyla Life Sciences, Inc.4$48
Assertio Therapeutics, Inc.3$45
Acorda Therapeutics, Inc2$40
Arbor Pharmaceuticals, Inc.3$39
GE HealthCare2$39
Abbott2$33
Axsome Therapeutics, Inc.2$33
Boston Scientific2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,394 in reported general payments places this provider in the 75th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$68,058
Medicare patients
264
Services billed
530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod33$367,396
OctagamImmun Globg(Igg)/Malt/Iga Ov5012$200,706
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$161,207
IngrezzaValbenazine Tosylate19$158,016
BotoxOnabotulinumtoxina96$129,713
ZeposiaOzanimod Hydrochloride14$127,703
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5023$101,533
TecfideraDimethyl Fumarate11$97,006
UbrelvyUbrogepant90$91,315
NuplazidPimavanserin Tartrate14$77,830
LamictalLamotrigine64$65,633
EpidiolexCannabidiol (Cbd)22$63,931
Teriflunomide40$63,789
RytaryCarbidopa/Levodopa24$40,239
BriviactBrivaracetam25$34,964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$1,568$367,39633 claims
AbbVieBotox, Ubrelvy, Qulipta$2,319$241,040203 claims
PfizerOctagam, Nurtec Odt, Eliquis$433$229,93546 claims
CSL BehringPrivigen$214$161,20711 claims
Neurocrine Biosciences, Inc.Ingrezza$652$158,01619 claims
E.r. Squibb & Sons, L.L.C.Zeposia$73$127,70314 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$81$101,53323 claims
BiogenTecfidera$1,072$97,00611 claims
UCB, Inc.Briviact, Vimpat, Neupro$2,744$78,01873 claims
Acadia Pharmaceuticals IncNuplazid$374$77,83014 claims
Amneal Pharmaceuticals LLCRytary$191$40,23924 claims
Ipsen Biopharmaceuticals, IncDysport$300$31,75027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 361 neurology providers in Tennessee.

Other neurology in Kingsport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →